Active Ingredient History
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer (levonorgestrel) is biologically active. Norgestrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Loss of the LH surge inhibits ovulation and thereby prevents pregnancy. Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. NCATS
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acromegaly (Phase 2)
Adenomyosis (Early Phase 1)
Amenorrhea (Phase 4)
Anemia, Aplastic (Phase 1/Phase 2)
Anorexia Nervosa (Phase 2/Phase 3)
Arthritis, Rheumatoid (Phase 1)
Bariatric Surgery (Phase 4)
Body Weight (Phase 4)
Bone Density (Phase 2)
Bone Diseases, Metabolic (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Chlamydia Infections (Phase 4)
Contraception (Phase 4)
Contraception Behavior (Phase 4)
Contraception, Postcoital (Phase 4)
Contraceptive Agents (Phase 4)
Contraceptives, Oral (Phase 3)
Contraceptives, Oral, Combined (Phase 4)
Contraceptives, Postcoital (Phase 1)
Diabetes Mellitus (Phase 1)
Diabetes Mellitus, Type 2 (Phase 1)
Drug Interactions (Phase 1)
Dysmenorrhea (Phase 3)
Endometrial Hyperplasia (Phase 4)
Endometrial Neoplasms (Phase 2/Phase 3)
Endometriosis (Phase 4)
Epilepsies, Partial (Phase 1)
Epilepsy (Phase 4)
Fertility (Phase 4)
Growth and Development (Phase 1)
Headache (Phase 3)
Healthy Volunteers (Phase 4)
Hemostasis (Phase 2)
Hepatitis C (Phase 1)
Hepatitis C, Chronic (Phase 1)
HIV (Phase 4)
HIV Infections (Phase 4)
Infertility (Phase 4)
Infertility, Female (Phase 3)
Intrauterine Devices (Phase 4)
Intrauterine Devices, Medicated (Phase 4)
Libido (Phase 3)
Menopause (Phase 3)
Menorrhagia ()
Menstruation (Phase 3)
Menstruation Disturbances (Phase 3)
Metabolism (Phase 1/Phase 2)
Metrorrhagia (Phase 2)
Migraine Disorders (Phase 2)
Neisseriaceae Infections (Phase 4)
Obesity (Phase 4)
Osteoporosis (Phase 2)
Ovarian Diseases (Phase 4)
Ovarian Follicle (Phase 1)
Ovarian Neoplasms (Phase 2)
Ovulation (Phase 2)
Ovulation Inhibition (Phase 2)
Pain (Phase 2)
Pelvic Pain (Phase 3)
Pharmacokinetics (Phase 1)
Postpartum Period (Phase 4)
Pregnancy Complications (Phase 4)
Pregnancy, Unplanned (Phase 4)
Premenstrual Syndrome (Phase 3)
Primary Ovarian Insufficiency (Phase 3)
Quality of Life (Phase 4)
Thinness (Phase 4)
Uterine Diseases (Phase 4)
Uterine Hemorrhage (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
